Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetesMohammad Alhadj Ali, Colin Dayan, Martin Eichmann et al.|Science Translational Medicine|2017Cited by 215
Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trialDanijela Tatović, Laura Cook, Ashish Marwaha et al.|Nature Medicine|2024Cited by 40
The efficacy and safety of ustekinumab in adolescents newly diagnosed with type 1 diabetes: the USTEK1D RCTKymberley Carter, Colin Dayan, WY Cheung et al.|Efficacy and Mechanism Evaluation|2025Cited by 2
Proinsulin peptide immunotherapy in type 1 diabetes:safety data of a first in new-onset type 1 diabetes phase 1b trialMohammad Alhadj Ali, Colin M Dayan, Yuk-Fun; id_orcid 0000-0002-8518-8756 Liu et al.|Research Portal (King's College London)|2015Cited by 0